Human IgG1 LALA Isotype Control antibody (HyHEL-10) – vcMMAE

Description of Human IgG1 LALA Isotype Control antibody (HyHEL-10) - vcMMAE

PTX17885 is a non-binding isotype control antibody developed by ProteoGenix to support antibody-drug conjugate (ADC) research. It is derived from the HyHEL-10 monoclonal antibody, engineered as a human IgG1 backbone with LALA mutations in the Fc region to eliminate Fcγ receptor interactions and reduce nonspecific immune activation.

This antibody is conjugated to MMAE (Monomethyl Auristatin E), a potent antimitotic agent, using a cleavable c-ValCitPAB linker, which ensures drug release in the lysosomal environment. The conjugation was optimized for a Drug-to-Antibody Ratio (DAR) of 4, providing consistent and biologically relevant payload loading.

PTX17885 is a critical negative control in ADC development workflows. It lacks specificity for any mammalian antigen, making it ideal for assessing the safety and functionality of ADC components such as the linker and payload without antigen-mediated effects. It enables researchers to distinguish on-target versus off-target activity, evaluate systemic toxicity, and monitor non-specific cellular uptake or bystander effects.

Recommended applications include:

• In vitro cytotoxicity profiling of linker-drug systems
• In vivo pharmacokinetics and biodistribution studies
• Comparative toxicity analysis in preclinical models
• Validation of analytical and potency assays

With PTX17885, ProteoGenix provides a robust and reliable control tool for ADC design, development, and translational therapeutic antibody research. It is an essential component for any program aiming to optimize conjugation strategies while maintaining experimental rigor and data reproducibility.